BMC Microbiology (Feb 2022)

Long-term diosmectite use does not alter the gut microbiota in adults with chronic diarrhea

  • Kévin Da Silva,
  • Susie Guilly,
  • Florence Thirion,
  • Emmanuelle Le Chatelier,
  • Nicolas Pons,
  • Hugo Roume,
  • Benoît Quinquis,
  • Stanislav D. Ehrlich,
  • Nassima Bekkat,
  • Hélène Mathiex-Fortunet,
  • Harry Sokol,
  • Joël Doré

DOI
https://doi.org/10.1186/s12866-022-02464-7
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 11

Abstract

Read online

Abstract Background Diosmectite, a natural colloidal clay, has been used worldwide for a number of approved indications, including the treatment of chronic functional diarrhea. Here, we used high-resolution whole metagenome shotgun sequencing to assess the impact of a 5 weeks administration of diosmectite (3 g/sachet, 3 sachets/day) on the fecal microbiota of 35 adults with functional chronic diarrhea. Results Gut microbiota was not impacted by diosmectite administration. In particular, richness remained stable and no microbial species displayed a significant evolution. Segregating patients either by diosmectite response (non responder, early responder, late responder) or by nationality (Great-Britain or Netherlands) yielded the same results. Conclusion We concluded that no microbiota-related physiological alterations are expected upon long-term treatment with diosmectite. Trial registration Clinicaltrials.gov NCT03045926

Keywords